Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed (2025)

Historic Return on Capital Employed for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to 0.6%.

  • Silence Therapeutics' Return on Capital Employed fell 5100.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.6%, marking a year-over-year decrease of 5100.0%. This contributed to the annual value of 0.44% for FY2024, which is 1500.0% up from last year.
  • As of Q3 2025, Silence Therapeutics' Return on Capital Employed stood at 0.6%, which was down 5100.0% from 0.54% recorded in Q2 2025.
  • Silence Therapeutics' Return on Capital Employed's 5-year high stood at 0.09% during Q2 2024, with a 5-year trough of 0.6% in Q3 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.13% (2022), whereas its average is 0.21%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 1600bps in 2022, then plummeted by -5100bps in 2025.
  • Silence Therapeutics' Return on Capital Employed (Quarter) stood at 0.21% in 2021, then skyrocketed by 38bps to 0.13% in 2022, then increased by 3bps to 0.12% in 2023, then dropped by -1bps to 0.13% in 2024, then tumbled by -378bps to 0.6% in 2025.
  • Its last three reported values are 0.6% in Q3 2025, 0.54% for Q2 2025, and 0.49% during Q1 2025.